酸加载的自纳米乳化水凝基药物输送系统,用于抗桃菌病
Mohammad Sameer Khan1, Mahak Fatima1, Shadma Wahab2
1Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110062, India.
Nanomedicine (London, England)
|August 15, 2024
概括
充满酸 (GA) 的自纳米乳化药物输送系统 (SNEDDS) 显示出对治疗桃菌病的前景. 与传统的GA溶液相比,这些SNEDDS可以提高药物透率并减少刺激.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 菌类学 菌类学是指菌类学.
背景情况:
- 甲状腺炎是一种指甲真菌感染,由于药物透率差,因此存在治疗挑战.
- 传统疗法通常有效性有限,可能导致药物耐药性.
研究的目的:
- 开发和评估含酸 (GA) 的自纳米乳化药物输送系统 (SNEDDS),用于跨口输送.
- 评估GA-SNEDDS在治疗红斑瘤的疗效和安全性.
主要方法:
- 使用直接分散技术准备了SNEDDS.
- 描述涉及FTIR,DSC,显微镜和动态光散射.
- 评估了体外抗真菌活性,指甲透和安全性 (蛋试验).
主要成果:
- SNEDDS的颗粒大小为199.8nm,泽塔电位为-22.75mV.
- 在24小时内观察到70.34%的持续药物释放.
- 与GA溶液相比,GA-SNEDDS显示提高了指甲透率和减少了皮肤刺激.
结论:
- 含有GA的SNEDDS提供了一种可行的策略,可以改善桃病治疗.
- 这种配方增强了药物的有效性,并可能减轻抗真菌耐药性的发展.
相关概念视频
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...


